Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and chemotherapy in resectable stage IIIA NSCLC
NCT05157776Phase 3Unknown
- Sponsor
- Tongji University
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Tongji University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05157776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157776.